Page 87 - TD-4-2

Tumor Discovery DRGs in HCC prognosis and immunity

biomarker associated with favorable prognosis in gastric Ethics approval and consent to participate
cancer patients. Chen et al. reported that CD2AP can
31
32
be used as a diagnostic and prognostic biomarker in Not applicable.
patients with clear cell renal carcinoma and that DNA Consent for publication
hypermethylation plays a significant role in reducing
32
CD2AP expression. In addition, CD2AP was upregulated Not applicable.
in response to chronic hepatitis C virus infection, which Availability of data
stimulates viral transmission and steatosis by disrupting
insulin signaling. Targeting CD2AP may offer a strategy to Publicly available datasets were analyzed in this study.
alleviate hepatitis C virus infection and its associated liver Clinical data for 424 patients with HCC were obtained
pathology. 33 from the TCGA database (https://portal.gdc.cancer.gov/).
Therefore, CAPZB, FLNA, and CD2AP are anticipated References
to serve as novel molecular targets and offer valuable tools
for assessing the effects of immunotherapy. However, this 1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics
study has several limitations. For instance, data sourced 2022: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
from public databases were used for bioinformatics 2024;74(3):229-263.
analysis, and the prediction results may be biased due to
variations among different databases. Additional studies doi: 10.3322/caac.21834
are required to validate the prediction results. In addition, 2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics
the precise mechanism of CD2AP in HCC requires further 2020: GLOBOCAN estimates of incidence and mortality
investigation. worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2021;71(3):209-249.
5. Conclusion doi: 10.3322/caac.21660

This study identified that DRGs are associated with the 3. Zheng RS, Chen R, Han BF, et al. Cancer incidence and
prognosis and immune status of patients with HCC. Three mortality in China, 2022. Zhonghua Zhong Liu Za Zhi.
key genes (CAPZB, FLNA, and CD2AP) are crucial for 2024;46(3):221-231.
further elucidating the role of DRGs in HCC. In addition, doi: 10.3760/cma.j.cn112152-20240119-00035
targeting differentially expressed genes may offer new
approaches for diagnosing and treating HCC. Furthermore, 4. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A,
CD2AP has not yet been reported to be associated with Roberts LR. A global view of hepatocellular carcinoma:
Trends, risk, prevention and management. Nat Rev
HCC pathways and clinical treatment. Hence, it may serve Gastroenterol Hepatol. 2019;16(10):589-604.
as a novel tumor marker and offer a potential therapeutic
strategy for HCC. doi: 10.1038/s41575-019-0186-y
5. Villanueva A. Hepatocellular carcinoma. N Engl J Med.
Acknowledgments 2019;380(15):1450-1462.
None. doi: 10.1056/NEJMra1713263

Funding 6. Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances
in immunotherapy for hepatocellular carcinoma. Nat Rev
None. Gastroenterol Hepatol. 2021;18(8):525-543.
Conflict of interest doi: 10.1038/s41575-021-00438-0
7. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies
The authors declare they have no competing interests. for hepatocellular carcinoma. Nat Rev Clin Oncol.
2022;19(3):151-172.
Author contributions
doi: 10.1038/s41571-021-00573-2
Conceptualization: Shanshan Wang
Investigation: Yang Li 8. Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability
to disulfide stress mediates disulfidptosis. Nat Cell Biol.
Methodology: Xin Xie 2023;25(3):404-414.
Formal analysis: Moxian Chen
Writing – original draft: Qiang Li doi: 10.1038/s41556-023-01091-2
Writing – review & editing: Jiaqian Mo 9. Wang Z, Du X, Lian W, et al. A novel disulfidptosis-

Volume 4 Issue 2 (2025) 79 doi: 10.36922/td.8214